HER2-expressing cancers are treated by personalized drugs directed to block HER2 ligand binding and dimerization via antibodies (trastuzumab, pertuzumab), or alternatively by small molecules that inhibit HER2 function such as an HER2 kinase inhibitor (Trikerb). Here, ERBB2 is linked to cancer.